Gout is a major health problem in the United States; it affects 8.3 million people, which is approximately 4% of the adult population.
Gout is most often diagnosed and managed in primary care practices; thus, primary care physicians have a significant opportunity to improve patient outcomes. Following publication of the 2006 European League Against
Rheumatism (EULAR)
gout guidelines, significant new evidence has accumulated, and new treatments for patients with
gout have become available. It is the objective of these 2011 recommendations to update the 2006 EULAR guidelines, paying special attention to the needs of primary care physicians. The revised 2011 recommendations are based on the Grading of Recommendations Assessment, Development, and Evaluation approach as an evidence-based strategy for rating quality of evidence and grading the strength of recommendation formulated for use in clinical practice. A total of 26 key recommendations, 10 for diagnosis and 16 for management, of patients with
gout were evaluated, resulting in important updates for patient care. The presence of
monosodium urate crystals and/or tophus and response to
colchicine have the highest clinical diagnostic value. The key aspect of effective management of an acute
gout attack is initiation of treatment within hours of symptom onset. Low-dose
colchicine is better tolerated and is as effective as a high dose. When
urate-lowering
therapy (ULT) is indicated, the
xanthine oxidase inhibitors
allopurinol and
febuxostat are the options of choice.
Febuxostat can be prescribed at unchanged doses for patients with mild-to-moderate renal or hepatic impairment. The target of ULT should be a serum
uric acid level that is ≤ 6 mg/dL. For patients with refractory and tophaceous
gout, intravenous
pegloticase is a new treatment option. This article is a summary of the 2011 clinical guidelines published in Postgraduate Medicine. This article provides a streamlined, accessible overview intended for quick review by primary care physicians, with the full guidelines being a resource for those seeking additional background information and expanded discussion.